Caamtech, Inc.
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Feb 2038
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 28, 2027The maintenance fee for Crystalline 5-methoxy-n,n-diallyltryptamine compounds (US 11,739,060) comes due Feb 28, 2027. Unpaid by Aug 30, 2027, it lapses early.
- 1 fee due Mar 12, 2027The maintenance fee for Crystalline Psilacetin Derivatives (US 11,753,375) comes due Mar 12, 2027. Unpaid by Sep 13, 2027, it lapses early.
- 1 fee due Apr 10, 2027The maintenance fee for Crystalline bis-miprocin fumarate (US 11,780,808) comes due Apr 10, 2027. Unpaid by Oct 12, 2027, it lapses early.
- 1 fee due May 21, 2027The maintenance fee for Compositions comprising a serotonergic tryptamine compound (US 11,819,475) comes due May 21, 2027. Unpaid by Nov 22, 2027, it lapses early.
- 2 fees due Jul 2 to 30, 2027 · next Jul 2
- 1 fee due Sep 12, 2027The maintenance fee for Crystalline 4-hydroxy-N,N-di-n-propyltryptammonium (4-HO-DPT) salts (US 11,926,590) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.
- 1 fee due Nov 7, 2027The maintenance fee for Compositions and Methods Comprising a Combination of Serotonergic Drugs (US 11,974,984) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,471,439 | Compositions and Methods Comprising a Combination of Serotonergic Drugs In force · Medium confidence | In force | Medium confidence | |
| US 11,819,475 | Compositions comprising a serotonergic tryptamine compound In force · From the USPTO record | In force | From the USPTO record | |
| US 11,974,984 | Compositions and Methods Comprising a Combination of Serotonergic Drugs In force · Medium confidence | In force | Medium confidence | |
| US 10,933,073 | Compositions and Methods Comprising a Psilocybin Derivative In force · High confidence | In force | High confidence | |
| US 12,383,532 | Compositions and Methods Comprising a Combination of Serotonergic Drugs In force · Medium confidence | In force | Medium confidence | |
| US 11,332,441 | Crystalline N-methyl tryptamine derivatives In force · From the USPTO record | In force | From the USPTO record | |
| US 11,884,625 | Crystalline forms of psilacetin In force · From the USPTO record | In force | From the USPTO record | |
| US 12,187,680 | Crystalline forms of psilacetin In force · From the USPTO record | In force | From the USPTO record | |
| US 12,414,936 | Compositions Comprising a Serotonergic Tryptamine Compound In force · High confidence | In force | High confidence | |
| US 11,358,934 | Crystalline forms of psilacetin In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 30: 2 patents in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
19 pending · 8 abandoned · 8 no status recorded